Official Statistics: Mefloquine (Larium) Prescribing in the UK Armed Forces: 12 September 2016 to 31 March 2026

Why It Matters

The declining prescription rates signal a move toward safer, better‑tolerated malaria prophylaxis, directly affecting troop health and operational readiness. Continuous monitoring enables the MOD to refine drug‑policy decisions and mitigate adverse‑event risks.

Key Takeaways

• Mefloquine prescriptions tracked across MOD facilities from Sep 2016‑Mar 2026.
• New 2016 policy introduced stricter criteria for mefloquine use.
• Prescribing volume shows gradual decline as alternative prophylactics gain favor.
• Data supports ongoing review of malaria chemoprophylaxis safety in troops.

Pulse Analysis

Mefloquine, marketed as Lariam, has long been a cornerstone of malaria chemoprophylaxis for military personnel deployed to high‑risk, chloroquine‑resistant zones. Its once‑weekly dosing made it logistically attractive, yet neuropsychiatric side effects have raised concerns, prompting many armed forces to reassess its role. In the UK, the Ministry of Defence (MOD) historically relied on mefloquine alongside doxycycline and atovaquone‑proguanil to safeguard troops against malaria, a disease that can cripple operational capability and incur significant medical costs.

In September 2016 the MOD instituted a new prescribing policy that imposed tighter clinical criteria, mandated specialist review, and encouraged the use of alternatives with more favorable safety profiles. The latest bi‑annual bulletin, covering prescriptions from 12 September 2016 to 31 March 2026, reveals a clear downward trajectory in mefloquine use. While exact numbers are confidential, the trend aligns with broader NATO data showing a shift toward doxycycline and atovaquone‑proguanil, especially for long‑duration deployments where tolerability is paramount. The statistical series also tracks adverse‑event reports, illustrating a correlation between reduced prescribing and fewer documented side‑effect incidents.

The implications extend beyond drug choice. Robust prescribing data empower the MOD to conduct evidence‑based policy reviews, allocate medical resources efficiently, and maintain force readiness in malaria‑endemic theaters. As deployment patterns evolve and new prophylactic agents emerge, continuous surveillance will be essential to balance efficacy, safety, and logistical practicality. The 2026 bulletin thus serves as a benchmark for future assessments, underscoring the importance of data‑driven decision‑making in military health strategy.